当前位置: X-MOL 学术Virchows Arch. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
HNF-1β as an immunohistochemical marker for distinguishing chromophobe renal cell carcinoma and hybrid oncocytic tumors from renal oncocytoma.
Virchows Archiv ( IF 3.5 ) Pub Date : 2020-08-20 , DOI: 10.1007/s00428-020-02912-7
Jiyeon An 1 , Cheol Keun Park 1 , Moonsik Kim 1 , Jin Woo Joo 1 , Nam Hoon Cho 1
Affiliation  

The histologic features of renal oncocytoma (RO) are similar to those for the more aggressive chromophobe renal cell carcinoma (ChRCC). To assess immunohistochemical markers of the two, the sensitivity and specificity of cytokeratin 7 (CK7) and C-kit, as well as hepatocyte nuclear factor-1β (HNF-1β), were analyzed. Typical cases of ChRCC and RO at Severance Hospital between July 2014 and July 2018 were selected retrospectively. Among 44 cases, 17 were unanimously compatible with ChRCC, 16 were RO, and 11 cases were indeterminate. Samples from all selected cases were used for immunostaining with antibodies against CK7, C-kit, HNF-1β, and CD10. Immunostaining demonstrated complete loss of HNF-1β expression in 11 out of 17 (64.7%) ChRCC cases and a partial, but significant loss in > 50% of tumor cells in the remaining 6 cases (35.3%). In contrast, HNF-1β expression was preserved in tumor cells of RO cases. Fourteen of 17 ChRCC cases (82.4%) were diffusely positive for CK7, whereas cases of RO were focal positive or negative. C-kit staining did not show a significant difference between ChRCC and RO. Two of five ChRCC cases showing diffuse immunoreactivity for CD10 had poor prognoses of local invasion, distant metastasis, or death. Loss of HNF-1β expression is a useful marker with which to diagnose ChRCC, especially in cases with confusing histologic findings or equivocal CK7 staining. Additionally, CD10 staining in high-grade ChRCC aids in diagnosis and prediction of the clinical prognosis.



中文翻译:

HNF-1β是一种免疫组织化学标记物,用于区分发色性肾细胞癌和杂种嗜酸性粒细胞瘤与肾上皮细胞瘤。

肾肿瘤细胞瘤(RO)的组织学特征与更具侵略性的发色性肾细胞癌(ChRCC)的组织学特征相似。为了评估两者的免疫组织化学标记,分析了细胞角蛋白7(CK7)和C-kit以及肝细胞核因子-1β(HNF-1β)的敏感性和特异性。回顾性选择2014年7月至2018年7月在Severance医院发生的ChRCC和RO的典型病例。在44例病例中,有17例与ChRCC一致,16例为RO,11例不确定。来自所有选定病例的样品均用于针对CK7,C-kit,HNF-1β和CD10的抗体进行免疫染色。免疫染色显示17例(64.7%)ChRCC病例中有11例HNF-1β表达完全丧失,其余6例(35.3%)大于50%的肿瘤细胞部分但显着丧失。相反,RO患者的肿瘤细胞中HNF-1β的表达得以保留。在17例ChRCC病例中,有14例(82.4%)CK7弥漫阳性,而RO病例则为局灶性阳性或阴性。C-kit染色在ChRCC和RO之间没有显示显着差异。五分之二的ChRCC病例显示CD10弥漫性免疫反应,预后较差,预示局部浸润,远处转移或死亡。HNF-1β表达的丧失是诊断ChRCC的有用标志物,尤其是在组织学检查结果混乱或CK7染色模棱两可的情况下。此外,高级ChRCC中的CD10染色有助于诊断和预测临床预后。C-kit染色在ChRCC和RO之间没有显示显着差异。五分之二的ChRCC病例显示CD10弥漫性免疫反应,预后较差,预示局部浸润,远处转移或死亡。HNF-1β表达的丧失是诊断ChRCC的有用标志物,尤其是在组织学检查结果混乱或CK7染色模棱两可的情况下。此外,高级ChRCC中的CD10染色有助于诊断和预测临床预后。C-kit染色在ChRCC和RO之间没有显示显着差异。五分之二的ChRCC病例显示CD10弥漫性免疫反应,预后较差,预示局部浸润,远处转移或死亡。HNF-1β表达的丧失是诊断ChRCC的有用标志物,尤其是在组织学检查结果混乱或CK7染色模棱两可的情况下。此外,高级ChRCC中的CD10染色有助于诊断和预测临床预后。

更新日期:2020-08-20
down
wechat
bug